NSE: ALIVUS | BSE: 543322

Expensive Performer

Download real time

1142.90 0.30 (0.03%)

51.19% Gain from 52W Low

142.2K NSE+BSE Volume

NSE 19 May, 2025 3:16 PM (IST)

14,015.3

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Alivus Life Sciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALIVUS, BSE:543322 Alivus Life Sciences Ltd.

Alivus Life Sciences Ltd.

27 Jul 2021

1142.90

0.03%

IPO Note - Specialized API to be the game changer; Recommend Subscribe'

IPO Note: Alivus Life Sciences Ltd.

Prabhudas Lilladhar

We believe the company is well poised to maintain consistent service quality as well as assure supply chain availability with its 1) leading manufacturing capabilities in key APIs, 2) strong relationship with global clients, 3) cost...

Number of MF schemes increased from 11 to 18 in Mar 2025 qtr.

Alivus Life Sciences Ltd.

26 Jul 2021

1142.90

0.03%

Glenmark Life Sciences Limited IPO Note 26072021

IPO Note: Alivus Life Sciences Ltd.

HDFC Securities

Glenmark Life Sciences Limited IPO Note Issue Open: July 27 July 29 2021 Price Band: Rs. 695 720 *Issue Size: 21,022,222 eq shares (Fresh Issue of Rs.1060 cr + Offer for sale of 6,300,000 eq sh) Issue Size: Rs.1497.8-1513.6 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh

Alivus Life Sciences Ltd. is trading above all available SMAs

Alivus Life Sciences Ltd.

26 Jul 2021

1142.90

0.03%

GLENMARK LIFE SCIENCES LIMITED

IPO Subscribe: Alivus Life Sciences Ltd.

Angel Broking

Glenmark Life Sciences Limited (GLS) was incorporated on 23rd June, 2011. GLS is a wholly-owned subsidiary of the Promoter, Glenmark Pharmaceuticals Ltd. GLS operates two business lines Generic APIs (generics and complex APIs) and CDMO (including specialty). GLS is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in

Alivus Life Sciences Ltd. is trading above all available SMAs

Alivus Life Sciences Ltd.

26 Jul 2021

1142.90

0.03%

Glenmark Life Sciences Ltd. IPO Note

IPO Note: Alivus Life Sciences Ltd.

Ashika Research

20 Equity Shares and in multiples thereof. Public issue of 21,022,222 Equity shares of Face value Rs. 2 each, (Comprising of fresh issue of 14,722,222 Equity Shares* (Rs. 1060 cr.) and Offer for Sale of...

Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.

Alivus Life Sciences Ltd.

24 Jul 2021

1142.90

0.03%

Glenmark Life Sciences

IPO Note: Alivus Life Sciences Ltd.

AUM Capital

Glenmark Life Sciences (GLS) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells Active Pharmaceutical Ingridients (APIs) for gastro-intestinal disorders, antiinfectives and other therapeutic areas. As of March 2021, GLS had a portfolio of 120 molecules globally and sold APIs in India and exported APIs to multiple countries in Europe, North America, Latin America,...

Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.

Alivus Life Sciences Ltd.

24 Jul 2021

1142.90

0.03%

GLENMARK LIFE SCIENCES LTD

IPO Note: Alivus Life Sciences Ltd.

Ventura

IPO NOTE

Number of MF schemes increased from 11 to 18 in Mar 2025 qtr.

Alivus Life Sciences Ltd.

23 Jul 2021

1142.90

0.03%

Glenmark Life Sciences Ltd : IPO

IPO Note: Alivus Life Sciences Ltd.

ICICI Securities Limited

Leadership in select APIs, strong relation with large companies GLS is a leading developer, manufacturer of select high value, noncommoditised APIs in chronic therapeutic areas, including CVS, CNS & pain management, diabetes and continue to branch into other APIs. It has strong market share in select specialised APIs like Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). Total market size in sales terms for GLS' portfolio of 120 molecules globally was estimated at ~US$142 billion in 2020 and is expected to grow ~6.8% in the...

Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.

VOTE: Is Glenmark Life Sciences Ltd. worth buying?

123 Votes:

Buy 75.61%

Sell 13.01%

Hold 11.38%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf